Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05271409




Registration number
NCT05271409
Ethics application status
Date submitted
28/02/2022
Date registered
9/03/2022
Date last updated
29/05/2024

Titles & IDs
Public title
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Scientific title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab As Monotherapy Or In Addition To Baseline Therapy In Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Secondary ID [1] 0 0
WN43194
Universal Trial Number (UTN)
Trial acronym
Meteoroid
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Satralizumab
Other interventions - Placebo

Experimental: Group A: Satralizumab - In the double-blind treatment period, participants will receive satralizumab at Weeks 0, 2, 4 (loading doses) and maintenance doses every 4 weeks (Q4W) thereafter. In the OLE period, all participants will receive open label treatment with satralizumab.

Placebo Comparator: Group B: Placebo - In the double-blind treatment period, participants will receive satralizumab matching placebo at Weeks 0, 2, 4 (loading doses) and maintenance doses every 4 weeks (Q4W) thereafter. In the OLE period, all participants will receive open label treatment with satralizumab.


Treatment: Drugs: Satralizumab
Study drug will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.

Other interventions: Placebo
Placebo will be administered by SC injection in the abdominal or femoral region after all other study-related procedures have been performed at a site visit.
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time from randomization to the first occurrence of a MOGAD relapse in the DB treatment period, as determined by an adjudication committee (CEC)
Timepoint [1] 0 0
Up to approximately 44 months
Secondary outcome [1] 0 0
Annualized rate of adjudicated MOGAD relapses
Timepoint [1] 0 0
Up to approximately 44 months
Secondary outcome [2] 0 0
Annualized rate of active lesions on MRI of the neuroaxis
Timepoint [2] 0 0
Up to approximately 44 months
Secondary outcome [3] 0 0
Proportion of participants receiving rescue therapy
Timepoint [3] 0 0
Up to approximately 44 months
Secondary outcome [4] 0 0
Annualized rate of inpatient hospitalizations
Timepoint [4] 0 0
Up to approximately 44 months

Eligibility
Key inclusion criteria
Inclusion criteria

- Participants who are aged >=12 years at the time of signing Informed Consent Form

- Confirmed diagnosis of MOGAD with a history of >=1 MOGAD relapse in the 12 months
prior to screening or >=2 attacks in the 24 months prior to screening

- Expanded Disability Status Scale (EDSS) score of 0-6.5 at screening

- Best corrected visual acuity (HCVA) better than 20/800 in each eye at screening

- Participants receiving either no or ongoing chronic immunosuppressant treatment (IST)
for MOGAD at the time of screening

- For women of childbearing potential: participants who agree to remain abstinent or use
adequate contraception during the treatment period and for at least 3 months after the
final dose of satralizumab
Minimum age
12 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion criteria

- Presence of aquaporin-4-antibodies (AQP4-IgG) in the serum

- History of anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis

- Any concomitant disease other than MOGAD that may require treatment with ISTs or OCS
or intravenous (IV) corticosteroids at doses >20 mg prednisone equivalent per day for
>21 days during the study

- Participants who are pregnant or breastfeeding, or intending to become pregnant during
the study or within 3 months after the final dose of satralizumab

- Participants with active or presence of recurrent bacterial, viral, fungal,
mycobacterial infection, or other infection at baseline

- Participants with evidence of latent or active tuberculosis (excluding patients
receiving chemoprophylaxis for latent tuberculosis infection)

- Participants with positive screening tests for hepatitis B and C

- Receipt of live or live attenuated vaccine within 6 weeks prior to baseline

- History of severe allergic reaction to a biologic agent

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/08/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/12/2028
Actual
Sample size
Target
152
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Recruitment hospital [1] 0 0
Brain and Mind Research Institute - Camperdown
Recruitment hospital [2] 0 0
John Hunter Hospital - New Lambton
Recruitment hospital [3] 0 0
Sydney Children's Hospital - Randwick
Recruitment hospital [4] 0 0
Royal North Shore Hospital; Department of Neurology - St Leonards
Recruitment hospital [5] 0 0
Box Hill Hospital; Department of Neurology - Box Hill
Recruitment hospital [6] 0 0
Royal Melbourne Hospital; Department of Neurology - Parkville
Recruitment hospital [7] 0 0
Perron Institute for Neurological and Translational Science - Nedlands
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2305 - New Lambton
Recruitment postcode(s) [3] 0 0
2031 - Randwick
Recruitment postcode(s) [4] 0 0
2065 - St Leonards
Recruitment postcode(s) [5] 0 0
3128 - Box Hill
Recruitment postcode(s) [6] 0 0
3050 - Parkville
Recruitment postcode(s) [7] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
South Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Wisconsin
Country [19] 0 0
Brazil
State/province [19] 0 0
PR
Country [20] 0 0
Brazil
State/province [20] 0 0
RJ
Country [21] 0 0
Brazil
State/province [21] 0 0
RS
Country [22] 0 0
Brazil
State/province [22] 0 0
SP
Country [23] 0 0
Canada
State/province [23] 0 0
Ontario
Country [24] 0 0
Canada
State/province [24] 0 0
Quebec
Country [25] 0 0
China
State/province [25] 0 0
Beijing City
Country [26] 0 0
China
State/province [26] 0 0
Changsha City
Country [27] 0 0
China
State/province [27] 0 0
Chengdu City
Country [28] 0 0
China
State/province [28] 0 0
Chongqing
Country [29] 0 0
China
State/province [29] 0 0
Guangzhou
Country [30] 0 0
China
State/province [30] 0 0
Hangzhou City
Country [31] 0 0
China
State/province [31] 0 0
Shanghai City
Country [32] 0 0
China
State/province [32] 0 0
Shanghai
Country [33] 0 0
China
State/province [33] 0 0
Taiyuan
Country [34] 0 0
China
State/province [34] 0 0
Tianjin
Country [35] 0 0
China
State/province [35] 0 0
Wuhan City
Country [36] 0 0
France
State/province [36] 0 0
Bron
Country [37] 0 0
France
State/province [37] 0 0
Paris
Country [38] 0 0
France
State/province [38] 0 0
Toulouse
Country [39] 0 0
Germany
State/province [39] 0 0
Berlin
Country [40] 0 0
Germany
State/province [40] 0 0
Bochum
Country [41] 0 0
Germany
State/province [41] 0 0
Datteln
Country [42] 0 0
Germany
State/province [42] 0 0
Düsseldorf
Country [43] 0 0
Germany
State/province [43] 0 0
Kiel
Country [44] 0 0
Germany
State/province [44] 0 0
Mannheim
Country [45] 0 0
Germany
State/province [45] 0 0
Munich
Country [46] 0 0
Israel
State/province [46] 0 0
Jerusalem
Country [47] 0 0
Italy
State/province [47] 0 0
Lazio
Country [48] 0 0
Italy
State/province [48] 0 0
Lombardia
Country [49] 0 0
Italy
State/province [49] 0 0
Piemonte
Country [50] 0 0
Italy
State/province [50] 0 0
Sicilia
Country [51] 0 0
Italy
State/province [51] 0 0
Veneto
Country [52] 0 0
Japan
State/province [52] 0 0
Chiba
Country [53] 0 0
Japan
State/province [53] 0 0
Fukuoka
Country [54] 0 0
Japan
State/province [54] 0 0
Fukushima
Country [55] 0 0
Japan
State/province [55] 0 0
Hyogo
Country [56] 0 0
Japan
State/province [56] 0 0
Kanagawa
Country [57] 0 0
Japan
State/province [57] 0 0
Miyagi
Country [58] 0 0
Japan
State/province [58] 0 0
Osaka
Country [59] 0 0
Japan
State/province [59] 0 0
Saitama
Country [60] 0 0
Japan
State/province [60] 0 0
Tokyo
Country [61] 0 0
Korea, Republic of
State/province [61] 0 0
Goyang-si
Country [62] 0 0
Korea, Republic of
State/province [62] 0 0
Seoul

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Hoffmann-La Roche
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Chugai Pharmaceutical
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The main objective of the study is to evaluate the efficacy of satralizumab compared with
placebo based on time from randomization to the first occurrence of an adjudicated MOGAD
relapse in the double-blind (DB) treatment period
Trial website
https://clinicaltrials.gov/ct2/show/NCT05271409
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Reference Study ID Number: WN43194, https://forpatients.roche.com/
Address 0 0
Country 0 0
Phone 0 0
888-662-6728 (U.S.)
Fax 0 0
Email 0 0
global-roche-genentech-trials@gene.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05271409